Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 7 of 8« First...45678

Certain Patients with Type 2 Diabetes Less Likely to Suffer Heart Failure While Taking New Class of Antidiabetic Drug

Seniors with type 2 diabetes or those with diabetic complications were less likely to be hospitalized for heart failure while taking a sodium-glucose co-transporter 2 (SGLT2) inhibitor compared to dipeptidyl peptidase-4 (DPP4) inhibitors, another new class of oral antidiabetic drug, according to a study released in Cardiovascular Diabetology and conducted by Anthem Inc. and HealthCore.

Read More »

Healthcare Marketers Say Few Ad Agencies Are Really Good Listeners

Healthcare advertising agencies need to sharpen their listening skills according to a new HCB Health survey.

Read More »

GSK bets on pioneering cancer therapy with Adaptimmune deal

GlaxoSmithKline has licensed the rights to Adaptimmune’s pioneering T-cell therapy program to boost its pipeline in oncology, one of four areas the company has prioritized for research and development.

Read More »

Lilly Cuts 3,500 Jobs, Shuts Down 2 R&D Sites

Eli Lilly and Company announced the company plans to cut 3,500 jobs. The majority of the job cuts will be in the U.S., and include voluntary early retirement programs.

Read More »

Convert Prior Authorization Abandonments to Rx Fulfillments and Stop Leaving Money on the Table

A very high percentage of Prior Authorization (PA) requests are approved…but about 40% of these prescriptions are abandoned during the PA process, around 74.4 million prescriptions a year.

Read More »

Bristol-Myers kidney cancer drug meets early success, study stopped

Bristol-Myers Squibb Co. said the success of the company’s combination therapy to improve overall survival in kidney cancer patients helped it end the trial early, despite having reported mixed results on other main goals earlier.

Read More »

FDA Orders 6 Partial or Full Clinical Holds on Celgene’s Blood Cancer Studies

The U.S. FDA placed a partial clinical hold on five of Celgene Corporation’s clinical trials and a full clinical hold on one of the company’s clinical trials in its FUSION program.

Read More »

Patient Death Forces Alnylam to Suspend Dosing in Hemophilia Trial, Stock Plunges

Alnylam Pharmaceuticals indicated that the company suspended its Phase II trial of fitusiran for hemophilia A after a patient died from a thrombotic event, pending further investigation.

Read More »

Quest to offer cholesterol testing without fasting requirement

Quest Diagnostics Inc. will use a more precise method of calculating levels of “bad” LDL cholesterol that no longer requires fasting prior to blood draw, a development likely to delight patients who previously had to refrain from eating for up to 12 hours before testing.

Read More »

Positive lung drug trial opens path to U.S. market for Circassia

AstraZeneca said its drug Duaklir improved lung function in chronic obstructive pulmonary disease (COPD) patients in a new study, paving the way for likely approval in the U.S., where the commercial rights are held by Britain’s Circassia.

Read More »

New AstraZeneca, Amgen drug looks strong rival in severe asthma

A new kind of injectable biotech treatment for severe asthma from AstraZeneca and Amgen promises to help a much broader range of patients than existing medicines such as GlaxoSmithKline’s Nucala.

Read More »

Verastem Soars as Blood Cancer Drug Succeeds in Phase III Study

Verastem, Inc.’s experimental blood cancer drug hit its endpoints in a Phase III trial and the news sent shares of company stock up more than 30 percent.

Read More »

Merck & Co. Takes Out Immuno-Oncology Startup in $603 Million Deal

Merck is complementing the company’s immuno-oncology platform and lead PD-1 inhibitor Keytruda with the newly acquired pipeline of a three-year-old German startup.

Read More »

France’s Servier to face trial over Mediator weight-loss drug

Drug maker Servier and the French drug regulator will face trial over weight-loss pill Mediator, believed to have caused at least 500 deaths in one of France’s worst health scandals, the prosecutor’s office said.

Read More »

Roche lung cancer drug Alecensa slashes brain risk in tests

Patients taking Roche’s targeted lung cancer drug Alecensa have a far lower risk of their disease spreading in the brain than those on Pfizer’s Xalkori, new clinical trial data show.

Read More »

Novo Nordisk settles U.S. probe over diabetes drug for nearly $58.7 million

  (Reuters) – Novo Nordisk will pay nearly $58.7 million to resolve claims the drugmaker’s sales staff downplayed the importance of U.S. Food and Drug Administration-mandated warnings about the cancer risks of its diabetes medication Victoza. The U.S. Justice Department said Tuesday’s settlement would resolve claims Novo Nordisk supplied its sales representatives with information to […]

Read More »

GE Healthcare Launches First-Ever Mammography System that Allows Patients to Control their Compression by Remote Control

GE Healthcare announced FDA 510(k) clearance of an industry-first, patient-assisted mammography device that literally puts women in control of their mammograms.

Read More »

U.S. judge invalidates Mallinckrodt patents on respiratory treatment

A federal judge in Delaware invalidated patents held by Mallinckrodt Pharmaceuticals on its Inomax respiratory treatment system.

Read More »

Insmed’s lung drug meets main goal in key study, shares soar

Insmed Inc. said its drug for the treatment of a rare lung disorder met the main goal in a key study, sending its shares soaring in premarket trading.

Read More »

Device maker Teleflex boosts urology business with NeoTract buy

Medical device maker Teleflex Inc. said on Tuesday it would buy privately held NeoTract Inc. to strengthen its portfolio of urology devices in its second billion-dollar deal in the past nine months.

Read More »

Page 7 of 8« First...45678

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

August 2018 Focus: Top 200 Meds, Year After Launch, VR/AR and more!

Subscribe

Ad Right Bottom